Antibody formation following botulinum toxin type a (Dysport) injection in children with intractable bladder hyper-reflexia

Urology

Volumn 76, Issue 1, 2010, Pages 233-237

  Kajbafzadeh, Abdol Mohammad ^a,b   Nikfarjam, Laleh ^a   Mahboubi, Amir Hassan ^a   Dianat, Seyed Saeid ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b NONE   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

BOTULINUM TOXIN A; MUSCLE RELAXANT AGENT;

ADOLESCENT; ANTIBODY PRODUCTION; ARTICLE; BLADDER DISEASE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DETRUSOR MUSCLE; FEMALE; HUMAN; HYPERREFLEXIA; INTRACTABLE BLADDER HYPERREFLEXIA; MALE; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; TREATMENT OUTCOME; URETER; URINE INCONTINENCE; IMMUNOLOGY; INTRAVESICAL DRUG ADMINISTRATION; NEUROGENIC BLADDER;

ADMINISTRATION, INTRAVESICAL; ADOLESCENT; ANTIBODY FORMATION; BOTULINUM TOXIN TYPE A; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; MALE; NEUROMUSCULAR AGENTS; URINARY BLADDER, NEUROGENIC;

EID: 77955877125     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2010.03.023     Document Type: Article

References (18)

1. Dressler D. Clinical presentation and management of antibodyinduced failure of botulinum toxin therapy. Mov Disord. 2004;19 (Suppl 8):S92-S100. (Pubitemid 38967517)
2. Jankovic J, Vuong KD, Ahsan J. Comparison of efficacy and immunogenicity of original versus current botulinum toxin in cervical dystonia. Neurology. 2003;60:1186-1188. (Pubitemid 36418786)
3. Kessler KR, Skutta M, Benecke R. Long-term treatment of cervical dystonia with botulinum toxin A: Efficacy, safety, and antibody frequency. German Dystonia Study Group. J Neurol. 1999;246:265-274. (Pubitemid 29229352)
4. Chapple C, Patel A. Botulinum toxin-new mechanisms, new therapeutic directions? Eur Urol. 2006;49:606-608. (Pubitemid 43374719)
5. Atassi MZ. Basic immunological aspects of botulinum toxin therapy. Mov Disord. 2004;19(Suppl 8):S68-S84. (Pubitemid 38967515)
6. Schulte-Baukloh H, Bigalke H, Miller K, et al. Botulinum neurotoxin type A in urology: Antibodies as a cause of therapy failure. Int J Urol. 2008;15:407-415; [Discussion:415]. (Pubitemid 351623889)
7. Brueggemann N, Doegnitz L, Harms L, et al. Skin reactions after intramuscular injection of botulinum toxin A: A rare side effect. J Neurol Neurosurg Psychiatry. 2008;79:231-232. (Pubitemid 351236571)
8. Schulte-Baukloh H, Bigalke H, Heine G, et al. Antibodies against botulinum neurotoxin type A as a cause of treatment failure after the first detrusor injection. Urology. 2007;69(575):e513-e575.
9. Dressler D. Clinical features of antibody-induced complete secondary failure of botulinum toxin therapy. Eur Neurol. 2002;48:26-29.
10. Kajbafzadeh AM, Moosavi S, Tajik P, et al. Intravesical injection of botulinum toxin type a: Management of neuropathic bladder and bowel dysfunction in children with myelomeningocele. Urology. 2006;68:1091-1096; [Discussion:1096-1097]. (Pubitemid 44750177)
11. Schurch B, Stohrer M, Kramer G, et al. Botulinum-A toxin for treating detrusor hyperreflexia in spinal cord injured patients: A new alternative to anticholinergic drugs? Preliminary results. J Urol. 2000;164:692-697. (Pubitemid 30637604)
12. Steinman A, Chaffer M, Elad D, et al. Quantitative analysis of levels of serum immunoglobulin G against botulinum neurotoxin type D and association with protection in natural outbreaks of cattle botulism. Clin Vaccine Immunol. 2006;13:862-868. (Pubitemid 44409624)
13. Park JB, Simpson LL, Anderson TD, et al. Immunologic characterization of spasmodic dysphonia patients who develop resistance to botulinum toxin. J Voice. 2003;17:255-264. (Pubitemid 36666391)
14. Kranz G, Sycha T, Voller B, et al. Neutralizing antibodies in dystonic patients who still respond well to botulinum toxin type a. Neurology. 2008;70:133-136.
15. Rapp DE, Lucioni A, Bales GT. Botulinum toxin injection: A review of injection principles and protocols. Int Braz J Urol. 2007; 33:132-141.
16. Bigalke H, Wohlfarth K, Irmer A, et al. Botulinum A toxin: Dysport improvement of biological availability. Exp Neurol. 2001; 168:162-170. (Pubitemid 32195268)
17. Dolimbek BZ, Jankovic J, Atassi MZ. Cross reaction of tetanus and botulinum neurotoxins A and B and the boosting effect of botulinum neurotoxins A and B on a primary anti-tetanus antibody response. Immunol Investig. 2002;31:247-262. (Pubitemid 35397080)
18. Sharma SK, Ferreira JL, Eblen BS, et al. Detection of type A, B, E, and F Clostridium botulinum neurotoxins in foods by using an amplified enzyme-linked immunosorbent assay with digoxigeninlabeled antibodies. Appl Environ Microbiol. 2006;72:1231-1238. (Pubitemid 43271231)